Barclays analyst Carter Gould maintains $Eli Lilly and Co (LLY.US)$ with a buy rating, and maintains the target price at $975.
According to TipRanks data, the analyst has a success rate of 48.1% and a total average return of 8.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Eli Lilly and Co (LLY.US)$'s main analysts recently are as follows:
In the wake of the Q3 earnings report, the scrutiny of Zepbound scripts and inventory levels may intensify among investors. Nevertheless, the demand for GLP1 is perceived to remain robust. Eli Lilly is considered to sustain its position as a prime growth narrative within the U.S. large-cap biopharma sector.
Eli Lilly experienced a fluctuating quarter with its Mounjaro and Zepbound products. Nonetheless, reassurances were given that the inconsistencies with Mounjaro and Zepbound were linked to inventory movements rather than supply and demand issues. Despite the third-quarter challenges, the overall stance on Eli Lilly remains optimistic, although projections for Mounjaro and Zepbound have been slightly reduced.
The recent adjustment of the price target for Eli Lilly reflects the implications of the Q3 report. The shortfall in tirzepatide sales indicates a significant effort is needed in Q4, considering the fluctuations in channel inventories and the timing of direct-to-consumer activities.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
巴克萊銀行分析師Carter Gould維持$禮來 (LLY.US)$買入評級，維持目標價975美元。
根據TipRanks數據顯示，該分析師近一年總勝率為48.1%，總平均回報率為8.9%。
此外，綜合報道，$禮來 (LLY.US)$近期主要分析師觀點如下：
在第三季度業績發佈之後，投資者對Zepbound腳本和庫存水平的審查可能會加強。儘管如此，人們認爲對GLP1的需求仍然強勁。禮來公司被認爲將繼續保持其作爲美國大型生物製藥行業主要增長公司的地位。
禮來公司的Mounjaro和Zepbound產品經歷了季度波動。儘管如此，有人保證，與Mounjaro和Zepbound的不一致之處與庫存變動有關，而不是與供需問題有關。儘管第三季度面臨挑戰，但禮來公司的總體立場仍然樂觀，儘管對Mounjaro和Zepbound的預測略有下降。
最近對禮來公司目標股價的調整反映了第三季度報告的影響。考慮到渠道庫存的波動和直接面向消費者的活動的時機，替塞帕肽銷售的短缺表明，第四季度需要做出重大努力。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
